Skip to main content

Table 1 Baseline characteristics, overall and by group

From: Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease

Characteristic

Total (N = 20)

Bexarotene (n = 16)

Placebo (n = 4)

Age at screening, yr

75.5 ± 6.8

74.9 ± 6.6

78.1 ± 8.0

Male sex

7 (35.0)

6 (37.5)

1 (25.0)

White race

19 (95.0)

15 (93.8)

4 (100.0)

Years of education

14.2 ± 4.7

14.7 ± 4.9

12.3 ± 3.3

Years of cognitive symptoms

4.3 ± 1.9

4.6 ± 1.9

2.8 ± 0.96

MMSE total score

14.4 ± 3.8

13.7 ± 3.7

17.0 ± 3.6

ADAS-Cog scorea

48.0 ± 9.8

49.9 ± 8.9

40.3 ± 10.7

CDS-SOB scorea

1.4 ± 0.56

1.4 ± 0.55

1.1 ± 0.63

NPI scorea

8.4 ± 8.1

8.7 ± 8.6

7.0 ± 6.4

ADCS-ADL scorea

55.9 ± 12.9

53.7 ± 13.1

64.5 ± 8.2

Composite SUVr

1.40 (0.11)

1.41 (0.09)

1.37 (0.16)

ApoE4 genotype

   

 Noncarriers

7 (35.0)

4 (25.0)

3 (75.0)

 Heterozygotes

7 (35.0)

6 (37.5)

1 (25.0)

 Homozygotes

6 (30.0)

6 (37.5)

0 (0.0)

  1. ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, ADCS-ADL Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale, CDR-SOB Clinical Dementia Rating Sum of Boxes, MMSE Mini Mental State Examination, NPI Neuropsychiatric Inventory, SUVr standardized uptake value ratio
  2. Values presented as mean ± standard deviation, or count (%)
  3. a Data not available for all subjects; missing values: ADAS-Cog score = 1, CDS-SOB score = 3, NPI score = 4, NPI distress score = 4, ADCS-ADL score = 1